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Abstract: Hypertension is one of the most frequent cardiovascular risk factors. The population
of hypertensive patients includes some phenotypes whose blood pressure levels are particularly
difficult to control, thus putting them at greater cardiovascular risk. This is especially true of so-called
resistant hypertension (RH) and refractory hypertension (RfH). Recent findings suggest that the former
may be due to an alteration in the renin–angiotensin–aldosterone axis, while the latter seems to be
more closely related to sympathetic hyper-activation. Both these pathophysiological mechanisms are
also activated in patients with obstructive sleep apnoea (OSA). It is not surprising, therefore, that the
prevalence of OSA in RH and RfH patients is very high (as reflected in several studies) and that
treatment with continuous positive airway pressure (CPAP) manages to reduce blood pressure levels
in a clinically significant way in both these groups of hypertensive patients. It is therefore necessary
to incorporate into the multidimensional treatment of patients with RH and RfH (changes in lifestyle,
control of obesity and drug treatment) a study of the possible existence of OSA, as this is a potentially
treatable disease. There are many questions that remain to be answered, especially regarding
the ideal combination of treatment in patients with RH/RfH and OSA (drugs, renal denervation,
CPAP treatment) and patients’ varying response to CPAP treatment.
Keywords: Resistant hypertension; Refractory hypertension; Obstructive sleep apnoea; Continuous
positive airway pressure
1. Introduction
Hypertension is one of the most common modifiable risk factors for the development of cardiovascular
disease and mortality. The global prevalence of hypertension, based on office blood pressure (BP)
measurements, has been estimated at 1.13 billion individuals worldwide in 2015, with a prevalence in
adults of 30–45% [1], and with half of these patients not achieving any adequate BP control [2]. There are
some difficult-to-treat phenotypes, such as those patients with resistant hypertension (RH) [3] and
refractory hypertension (RfH) [4].
RH and RfH are characterized by an incomplete response to antihypertensive therapy, which makes
it particularly challenging to identify potentially modifiable associated factors that could help to reduce
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BP levels. This identification is essential, however, in the light of the high cardiovascular impact of RH
and RfH, as they are associated with a 50% higher probability of developing a cardiovascular event or
damage to target organs than controlled hypertensive patients [5]
Obstructive sleep apnoea (OSA) is a common sleep disorder characterised by recurrent episodes
of upper airway obstruction that provoke intrathoracic pressure changes, sleep fragmentation,
intermittent hypoxia and increased sympathetic activity, triggering a variety of intermediate
mechanisms that mediate various clinical outcomes, including hypertension and a propensity to a
non-dipper circadian BP pattern [6]. Recent studies report a prevalence of moderate-to-severe OSA,
defined as an apnoea–hypopnoea index (AHI) of 15 or more events/h, in 10% to 21% of the general
population, and up to 49% in elderly subjects [7–10]. The prevalence of moderate-to-severe OSA
worldwide has been estimated at 425 million in adults aged from 30 to 69 years [11].
OSA and hypertension are closely related. OSA triggers direct and intermediate mechanisms
associated with the development and maintenance of hypertension, such as sympathetic hyperactivity [6].
The prevalence of OSA is as high as 30–50% in hypertensive patients [12], increasing to 70–85% in patients
with RH [13,14] and peaking at more than 90% in those with RfH [15]. In fact, of all the various secondary
causes of RH, OSA has been identified as the most common disorder associated with RH, accounting
for more than half of the patients in some studies [16]. Furthermore, it has been demonstrated that OSA
treatment with continuous positive airway pressure (CPAP) reduces BP by around 2–2.5 mmHg in patients
with hypertension and by up to 5 mmHg in those with RH [17]. All this evidence suggests that OSA and
its treatment may play an important role in RH.
In this review, we will cover the different aspects of the relationship between RH and OSA,
including the epidemiology of RH and RfH, the clinical association with OSA, the pathophysiological
links between the two disorders and the different therapies for RH and RfH (with a special focus on
OSA treatment), as well as potential future challenges in the interactions between OSA and RH.
2. Resistant and Refractory Hypertension Phenotypes: Definition and Epidemiology
RH was defined in the first American Heart Association (AHA) statement as those forms
of hypertension with no identifiable cause in which BP levels remain uncontrolled despite the use
of at least three antihypertensive drugs (including a diuretic) prescribed at optimal doses or are
controlled only by treatment with four or more antihypertensive drugs [18]. Based on this statement,
the prevalence of RH ranges from 12% to 15%, depending on whether the latter group of patients is
taken into consideration [19–21].
A more recent statement that took into account new evidence reported in the latest clinical studies
adapted the thresholds of clinical BP and provided greater details of the type, dose and frequency
of the drugs that patients should usually be taking to fulfil the definition of RH. This statement also
points out the importance of performing 24 h ambulatory blood pressure monitoring (ABPM) in the
assessment process for this type of patient [3].
One of the most important contributions in recent years has been the definition of a particular
subgroup within RH patients. Acelajado et al. [22], after a retrospective study of patients with RH
undertaken by a specialist hypertension unit, proposed a specific definition for those subjects who
never achieved BP control, regardless of the number of drugs added or the drug regime implemented:
this type of patient should be considered to be suffering from refractory hypertension (RfH). The patients
who satisfied this definition were taking an average of six drugs.
However, the first definition of RfH proposed by Acelajado et al. [22] has been modified to include
the requirement of antihypertensive treatment with a strict drug regime that controls the volume overload.
Accordingly, the AHA’s latest statement on hypertension [3] defined RfH as those forms of hypertension
that remain uncontrolled despite the administration of at least five antihypertensive drugs, including
a long-acting thiazide-like diuretic and a mineral-corticoid receptor antagonist. Based on this definition,
the prevalence of this hypertension phenotype is about 3% of patients with RH [23].
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Therefore, the key point for the fulfilment of the definition of RfH that satisfies all these requirements
is the failure to achieve BP control, despite adding more drugs and maximising the most effective
drugs while also reducing the volume overload.
Consequently, some significant differences have been reported in the clinical profiles of subjects
with RH and those with RfH. RfH patients seem to be younger [24–26], with a higher prevalence
of diabetes [24,25], cardiovascular disease [23,24], stroke [25] and chronic kidney disease [24,25].
3. Clinical and Epidemiological Association with OSA
High-quality evidence has shown that OSA and hypertension are closely related. It has been
established that about 50% of OSA patients suffer from hypertension and that roughly 30–50%
of hypertensive patients have OSA [12,27,28]. Several clinic-based studies (and a few epidemiological
studies) have shown that the association between OSA and RH is even stronger.
Cross-sectional studies have reported a high prevalence of OSA among patients with RH, ranging from
60–90%, depending on the AHI threshold used to define OSA [13,14,16,29–34] (Table 1). The relationship
between these two disorders was first described in 2001 by Logan et al. in a small series of 24
men and 17 women with RH who presented a surprisingly high prevalence (83%) of OSA [13].
Other researchers subsequently confirmed the close relationship between both disorders. Pedrosa et al.
closely studied a cohort of 125 RH patients for secondary causes of RH and found that moderate-to-severe
(AHI ≥ 15 events/h) OSA was by far the most common condition associated with RH, accounting for 64%
of all causes, with the second most common cause, primary aldosteronism, a long way behind at 5.6% [16].
In a similar study of 204 patients, OSA of any severity (AHI ≥ 5 events/h) was the most prevalent disorder
associated with RH, in 72.1% of cases [32].
Other studies have shown that the prevalence of OSA is significantly increased in patients with
RH compared to those with controlled hypertension. In a case control study of 63 patients with RT and
63 with controlled hypertension, OSA was present in 71% of the patients in the first group, compared to
only 38% in the second (p < 0.001) [35]. Ruttanaumpawan et al. also found a greater prevalence of OSA
in RH compared to controlled hypertension (81 vs. 55%, p = 0.03) [14]. In both studies, OSA was
a strong independent predictor of RH, with an adjusted OR of 3.99 to 4.8. In a large retrospective
cohort study using a database composed of 470,386 hypertensive individuals whose OSA diagnosis
was retrieved by means of ICD-9 codes, OSA was present in 9.6% of patients with RH, compared to
6.8% in non-RH patients [36].
It is well known that there are significant racial and ethnic disparities in hypertension prevalence,
with higher rates of RH in non-Hispanic blacks. In this respect, two studies have investigated
the association between OSA and RH in the black population [31,37]. The Jackson Heart Sleep
Study analysed 664 black adults with hypertension by means of home respiratory polygraphy [37].
After adjustment for confounders, patients with moderate-to-severe OSA (AHI ≥ 15 events/h) had
2.0 times (95% CI 1.14–3.67) higher odds of having RH than those with mild OSA, or no OSA. Another
study conducted on 200 black participants with hypertension in a primary care setting showed that
patients with RH were nearly 2.5 times more likely to be at high OSA risk than those with controlled
hypertension, after adjusting for age, gender and medical co-morbidities [31]. In this study, however,
OSA risk was assessed by using a screening tool and not a sleep test.
Abdel-Kader et al. have addressed the association between OSA, RH and chronic kidney disease
in a cohort composed of 224 community-based subjects without chronic kidney disease, 88 patients
with non-dialysis-dependent chronic kidney disease and 95 with end-stage renal disease by means
of unattended home polysomnography and home BP measurements [38]. The authors observed
a significant association between severe OSA (AHI ≥ 30 events/h) and end-stage renal disease (OR 7.1,
95% CI 2.2–23.2), whereas patients with non-dialysis-dependent chronic kidney disease and severe OSA
did not appear to be at increased risk of RH (OR 1.2, 95% CI 0.4–3.7) after accounting for confounders
such as age, sex, race and body mass index.
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It is notable that OSA patients with RH do not usually present typical OSA symptoms, particularly
excessive daytime somnolence (EDS). In this respect, one study observed that only 70% of patients with
OSA and RH were snorers and very few had witnessed apnoeas [29], whereas another study showed
that the Epworth Sleepiness Score (ESS) was not an adequate screening tool for OSA in patients with
RH, since less than 45% had EDS and the sensitivity and specificity of the ESS were below 55% [39].
According to these findings, OSA screening questionnaires based on symptoms would serve for little
in patients with RH. However, various studies that have assessed OSA risk via screening questionnaires
(usually the Berlin Questionnaire) have observed that two thirds of those subjects attending an RH
clinic were identified as being at high risk of OSA, and that the risk of OSA, as assessed by this
screening test, was significantly higher than in patients with controlled hypertension [31,39].
All the aforementioned evidence has led the scientific community to consider OSA as an important
contributing factor to hypertension and RH. In 2003, the Seventh Report of the Joint National Committee
on Prevention, Detection, Evaluation and Treatment of High Blood Pressure included OSA as a common
identifiable cause of hypertension [40], and in the 2017 hypertension guidelines, OSA was acknowledged
as a secondary contributor to RH and OSA screening was recommended for patients with RH or
RfH [41]. Moreover, considering that most of these patients are non-sleepy and may not have typical
OSA symptoms, it is recommended that every patient with at least chronic snoring and RH should
undergo a sleep study, due to the high risk of OSA.
Although it is unclear whether RfH is simply the most severe extreme of the RH spectrum
or whether it really constitutes a different clinical phenotype, it undoubtedly carries the greatest
cardiovascular risk. So far, however, only one study has investigated the association between OSA
and RfH [15]. In this multicentre cross-sectional Spanish study, Martinez-Garcia et al. analysed 229
consecutive patients with RH diagnosed by means of 24 h ABPM. All the participants underwent
a home respiratory polygraphy. Compared with RH patients, those with RfH had a twofold greater
risk of having severe OSA (OR 1.9, 95% CI 1.02–3.8). The prevalence of moderate (AHI ≥ 15 events/h)
and severe (AHI ≥ 30 events/h) OSA was 95.2% and 64.3%, respectively, in the RfH group, compared
to 81.8% and 48.6% for the RH group (p < 0.05 for both comparisons).
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Table 1. Studies that have investigated the association between resistant or refractory hypertension and sleep apnoea. Only those studies which have used a sleep test
(either respiratory polygraphy or conventional polysomnography) have been included. Studies that assessed sleep apnoea risk based on screening questionnaires have
not been included.
Studies Patients (n) Age (Years) Type of BP Measure SBP/DBP (mmHg) Type of Sleep Study (AHIThreshold to Define OSA) OSA Prevalence/AHI
Logan 2001 [13] 41 patients with resistant HT(24 men, 17 women)
57.2 (1.6)
Men 54.6 (1.8)
Women 58.3 (3.0)
24 h ABPM
SBP: 149.0 (2.6) in Men,
150.6 (3.7) in women
DBP: 86.3 (2.0) in Men, 83.7 (1.9) in women
PSG (AHI ≥ 10)
82.9%
(96% in men, 65% in women)
Mean AHI: 32.2 (4.5) in men,
14.0 (3.1) in women
Martinez-Garcia 2006 [29] 49 pts with resistant HT(40.8% men) 68.1 (9.1)
24 h ABPM
SBP: 152.5 (13)
DBP: 89.2 (8.5)
RP (AHI ≥ 10)
AHI ≥ 10: 71.4%
AHI ≥ 30: 40.8%
Mean AHI: 26.2 (19.5)
Gonçalves 2007 [35]
63 pts with resistant HT
(21 men, 42 women) and
63 pts with controlled HT
(23 men, 40 women)
59 (7) in both the resistant and
controlled HT groups
24 h ABPM
SBP: 141 (17) in the resistant HT group vs.
121 (10) in the controlled HT group
DBP: 84 (12) in the resistant HT group vs.
74 (7) in the controlled HT group
RP (AHI ≥ 10)
71% in the resistant HT group vs. 38% in the
controlled HT group (p < 0.001)
Men: 86% vs. 52% (p = 0.016)
Women: 64% vs. 30% (p = 0.002)
Prat-Ubunama 2007 [34] 71 pts with resistant HT 56.0 (9.9)
Office BP measurement
SBP: 155.8 (27)
DBP: 88.3 (15)
PSG (AHI ≥ 5) 85% (90% in men, 77% in women)Mean AHI: 24.1 (24.7) (Men 20.8, Women 10.8)
Lloberes 2010 [33] 62 pts with resistant HT(67.3% men) 59 (10)
24 h ABPM
SBP: 139.1 (1.6)
DBP: 80.9 (1.2)
PSG (AHI ≥ 5)
AHI ≥ 5: 90.3%
AHI ≥ 30: 70%
Mean AHI: 47.8 (23.4)
Pedrosa 2011 [16] 125 pts with resistant HT(43% men) 52 (10)
24 h ABPM
SBP: 176 (31)
DBP: 107 (19)
PSG (AHI ≥ 15)
AHI ≥ 15: 64%
AHI ≥ 30: 32%
Median AHI: 18 (interquartile range, 10–40)
Florczak 2013 [32] 204 pts with resistant HT(123 men, 81 women) 48.4 (10.6)
24 h ABPM
Daytime SBP: 145 (19), DBP: 90 (13)
Nightime SBP: 132 (19), DBP: 79 (12)
PSG (AHI ≥ 5) AHI ≥ 5: 72.1%AHI ≥ 30: 26.5%
Ruttanaumpawan 2009 [14]
42 pts with resistant HT and
22 pts with controlled HT,
matched for age, sex and BMI
56.5 (1.6) in resistant HT
group, 60.1 (1.8) in controlled
HT group
24 h ABPM in the resistant HT group
SBP: 149 (2)
DBP: 85 (1)
PSG (AHI ≥ 10)
81% in the resistant HT group vs. 55%
in the controlled HT group (p = 0.03)
Mean AHI: 24.9 (3.2) in the resistant
HT group vs. 16.5 (2.7) in the controlled
HT group (p = 0.13)
Johnson 2019 [37]
664 black participants with
HT (205 men), of whom 96
(14.5%) had resistant HT
64.9 (10.6) Office BP measurement RP (AHI ≥ 15)
25.7% of all HT patients.
Patients with resistant HT were 1.92 times
more likely (95%CI 1.15–3.20) to have OSA,
compared to those with controlled HT
Abdel-Kader 2012 [38]
407 patients (229 men,
178 women), distributed in:
224 from general population
without chronic
kidney disease,
88 non-dialysis-dependent
chronic kidney disease, and
95 with end-stage
renal disease
60.0 (7.2) for the non-chronic
kidney disease, 52.2 (14) for
the non-dialysis-dependent
chronic kidney disease, and
53.8 (14.9) for the end-stage
renal disease group
Office BP measurement
Resistant HT was present in 4.9%
of patients in the non-chronic kidney
disease, 35.2% of the
non-dialysis-dependent chronic kidney
disease, and 22.1% of the end-stage renal
disease group
PSG (AHI ≥ 30)
Resistant HT was associated with severe OSA
in participants with end-stage renal disease
(adjusted OR 7.1, 95%CI 2.2–23.2),
but not in the non-chronic kidney disease
(adjusted OR 3.5, 95%CI 0.8–15.4) or the
non-dialysis-dependent chronic kidney
disease groups (adjusted OR 1.2,
95%CI 0.4–3.7)
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Table 1. Cont.
Studies Patients (n) Age (Years) Type of BP Measure SBP/DBP (mmHg) Type of Sleep Study (AHIThreshold to Define OSA) OSA Prevalence/AHI
Bhandari 2016 [36]
Retrospective cohort study
of 470,386 individuals from
a health insurance database
65 (11)
HT and Resistant HT were identified by
ICD-9 specific diagnoses codes
SBP: 139 (20)
DBP: 75 (13)
Sleep apnoea was identified by
ICD-9 specific diagnoses codes or
by dispensation of positive
pressure therapy
9.6% in the resistant HT group vs. 6.8 in the
non-resistant HT group (p < 0.01).
Sleep apnoea was significantly more common
in the resistant HT group compared to the
non-resistant HT group (adjusted OR 1.16,
95%CI 1.12–1.19)
Martinez-Garcia 2018 * [15]
229 pts with resistant HT
(63% men). Of these,
42 (18.3%) had refractory HT
58.3 (9.6) for the resistant HT
group and 58.4 (8.5) for the
refractory HT group
24 h ABPM
Resistant HT
SBP: 141.6 (11.2)
DBP: 82.2 (10)
Refractory HT
SBP: 152.4 (13.9)
DBP: 85.6 (11.8)
RP (AHI ≥ 5)
AHI ≥ 5
Resistant HT: 89.3%
Refractory HT: 100%
(p = 0.027)
AHI ≥ 30:
Resistant HT: 48.6%
Refractory HT: 64.3%
(p = 0.044)
* This study investigate the association between OSA and refractory hypertension. HT: Hypertension; BMI: Body Mass Index; OSA: Obstructive Sleep Apnoea; SBP: Systolic Blood
Pressure; DBP: Diastolic Blood Pressure; AHI: Apnoea–Hypopnoea Index; ABPM: 24h-Ambulatory Blood Pressure Monitoring; RP: Respiratory Polygraphy; PSG: Polysomnography;
ICD: International Classification of the disease.
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4. Pathophysiological Links with Obstructive Sleep Apnoea (OSA)
As there appear to be crucial differences between the pathophysiology of RH and RfH (Figure 1),
there may also be significant differences in the ways that these two conditions are related to OSA.
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4.1. Resistant Hypertension
Despite the different pathophysiological mechanisms behind RH, fluid overload is considered
to be the main one [42]. Sympathetic hyperactivity also makes a contribution [43]. An excess of fluid
retention is caused by excessive salt intake and salt sensitivity [44], age, obesity, chronic kidney
disease and, most particularly, hyperdosteronism [45], which is associated with overactivation of the
renin–angiotensyn aldosterone axis. A wide range of studies have demonstrated the key role played
by intensive diuretic treatment, including a mineralocorticoid receptor antagonist, in achieving BP
control of RH patients, and this is considered to demonstrate the transcendental importance of this
mechanism in RH [46–48].
The high prevalence of OSA in resistant hypertensive patients could be explained by fluid
retention, mainly as a result of hyperaldosteronism. The negative thoracic pressure associated with
sleep apnoea causes fluid to move from the legs to the neck area when the patient is lying down [49],
resulting in an oedema of the parapharyngeal tissues that could propitiate upper airway obstruction.
The more severe the OSA, the greater the related sympathetic activity, and the subsequent stimulation
of the renin-angiotensin-aldosterone axis. This increased fluid retention can therefore imply not only
higher BP but also more parapharyngeal oedemas and apnoeas, thus creating a fatal vicious circle.
4.2. Refractory Hypertension
As mentioned above, RfH is defined as BP that remains uncontrolled despite therapy with at least
five drugs, including an intensive diuretic treatment that maximizes volume depletion, a long-acting
thiazide-like diuretic and a mineral-corticoid receptor antagonist [3]. It is not surprising, therefore,
that sympathetic over-activity is believed to be the main mechanism behind RfH, as confirmed by the
results of a comparative clinical study by Dudenbostel et al. of RfH and RH patients [23]. They found
a lower fluid content in those patients with RfH, reflected in a lower sodium dietary intake and lower
thoracic fluid content, assessed via an impedance cardiography study. They also reported findings
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in clinical and biomarker measures that suggested greater sympathetic activity, such as higher office
resting and ambulatory heart rate and higher 24 h urinary normetanephrine levels.
As in the case of RfH, sympathetic over-activity in OSA patients seems to be the main
pathophysiological mechanism explaining the syndrome’s pressor effect [6,15,50]. In these patients,
respiratory events and their related intermittent hypoxia trigger sympathetic hyperactivation, leading to
a high incidence and prevalence of hypertension. Other less important mechanisms, such as oxidative
stress, inflammation and endothelial dysfunction, also contribute to this effect [51]. For all these reasons,
it seems clear that this common pathophysiological syndrome has significant clinical implications.
5. Multidimensional Treatment
Despite the significant progress made in recent years with respect to the treatment of RH, several
aspects remain unclear. The situation is even worse as regards RfH, as there is nothing to test beyond
hypothesis [52].
5.1. Lifestyle Changes and Diet
The same recommendations about lifestyle changes given to the general hypertensive population
could also be considered suitable for RH patients, and so the need for weight reduction, sodium
restriction (2 gr/day), moderation of alcohol consumption and regular physical exercise (3–5 sessions
of 30–40 min weekly) should be advocated.
Nevertheless, some specific points still need to be clarified. Although weight loss does have
a significant effect on BP reduction, and might improve OSA when it is present [53], no trials to date
have demonstrated how effective it is in reducing BP specifically in RH patients. Furthermore, there are
doubts regarding salt intake. There is a significant linear relationship between sodium restriction and
BP reduction in subjects with RH, even at low levels (1.5–3 gr/day), and restrictions on salt intake could
reduce the severity of any concomitant OSA [54]. Although the clinical studies on this topic [44,55] have
confirmed reductions in daytime and night time BP, they have included only small numbers of patients
and have not cleared any doubts about long-term efficacy. Moreover, there seems to be a U-shaped
relationship between sodium restriction and cardiovascular mortality, as a radical restriction could
increase cardiovascular risk, despite lowering BP [56]. Other dietary measures that have proved
effective in reducing BP in the general hypertensive population, such as DASH (dietary approach
to stop hypertension) and the Mediterranean diet [57–59], have still not been specifically assessed
in RH patients.
5.2. Renal Denervation
The initial studies testing renal denervation treatment for RH patients raised expectations for this
procedure as a possible definitive therapy for both RH and RfH [60,61]. Furthermore, the efficacy of this
procedure did not seem to be influenced by the presence of OSA or otherwise, or its treatment [62,63].
Moreover, it might result in additional benefits for OSA and decrease its severity when it is concomitant [62].
However, the SYMPLICITY III study (NTC02041130) on 535 patients randomized to renal denervation vs.
sham procedure found no significant benefits for systolic blood pressure and raised doubts about efficacy
of the procedure, the most appropriate techniques for performing it and the most suitable candidates [64].
Therefore, as stated in most of the current guidelines, it is necessary to undertake more research to clarify
the indications for this procedure in RH patients [1,3].
5.3. Pharmacological Treatment
Pharmacological therapy has constituted the primary approach to the treatment of RH to date
and it has provided the main advances made in recent years, although some RfH patients never
achieve BP control. There is no longer any doubt about the efficacy of spironolactone in improving BP
control and it should be added to the baseline treatment, if possible, as a fourth drug (this treatment
should already include a diuretic at optimal dose) [48]. Spironolactone might also significantly reduce
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the severity of OSA, when it is present [65,66], and this could also be true of other diuretics [67,68].
However, the use of spironolactone is limited by side effects such as gynaecomastia, reported in 5%
of patients taking it [69], and contraindications such as chronic kidney disease (a glomerular filtration
rate under 45 mL/min and potassium level above 4.5 mmol/L), because it significantly increases the
risk of hyperkalemia, particularly in a dual renin angiotensin aldosterone system (RAAS) blockade
regimen [70]. Two further points need to be taken into account. On the one hand, the results of the
REACH registry, which included 6790 patients meeting the criteria of RH, followed for a mean time
of four years, showed that, even with good BP control, a higher number of anti-hypertensive drugs
may not reduce the long-term risk of an adverse cardiovascular outcome [19]. On the other hand,
in some patients, such as those with RfH, a mineralocorticoid receptor antagonist does not play
a determining role in the achievement of BP control, so new non-pharmacological strategies need to be
tested in such cases.
In addition to pharmacological treatment, the treatment of OSA with continuous positive airway
pressure (CPAP) might be an alternative means of achieving BP control in RH subjects with OSA,
due to its additional effect of lowering blood pressure in these patients [71–74]. Moreover, some RH or
RfH patients might be particularly susceptible to a significant drop in BP with this treatment [75].
5.4. CPAP Treatment
Although the definitions of resistant and refractory hypertension have changed over time,
the first study that can be considered an analysis of the effect of CPAP treatment on blood pressure
levels in patients with resistant/refractory hypertension was published by Logan et al. in 2003 [76].
More specifically, the authors analysed the acute effect of CPAP on 11 RH patients. During one single
night application, CPAP reduced systolic (S) BP by 12.3 mmHg and diastolic (D) BP by 4.8 mmHg.
These reductions persisted after two months of treatment, especially during the night. The authors
concluded that randomised clinical trials were needed to confirm their results. Since then, more than
20 studies have been published on different aspects of the effect of CPAP treatment in patients
with RH or RfH: nine randomised controlled trials [RCT] [17,71,77–83], two of them on the effect
on aldosterone concentration [79,82] and one on the effect on leptin concentration [84] (Table 2);
four observational trials [84–87]; five meta-analyses and systematic reviews [72,88–91]; and, finally,
five studies on additional topics, such as methodology [92], personalised medicine [75], adherence
to CPAP treatment [93] and the combined effect of CPAP and renal denervation [63]. The first RCT
on the effect of CPAP on BP levels in RH was performed by Lozano et al. in 2010 [77] in 64 patients
with ABPM-confirmed RH. Patients treated with CPAP (n = 20) showed a decrease in 24 h diastolic BP
(4.9 ± 6.4 vs. 0.1 ± 7.3 mmHg, p = 0.027) compared with the control group without CPAP. Moreover,
the number of patients with a dipping pattern significantly increased in the CPAP group (51.7% vs.
24.1%, P = 0.008). Patients who used CPAP > 5.8 h showed a greater reduction in 24h BP (6.98 mmHg
in diastolic blood pressure (DBP) and 9.71 mmHg in systolic blood pressure (SBP)). The largest RCT on
the effect of CPAP on BP levels in RH patients was the HIPARCO study (NTC00616265) undertaken by
the Spanish Sleep Network [17], in which 194 patients were randomised to CPAP (n = 98) or no CPAP
(n = 96) over 3 months. The CPAP group achieved a greater decrease in 24 h mean BP (3.1 mm Hg
[95% CI, 0.6 to 5.6]; P = 0.02) and 24 h DBP (3.2 mm Hg [95% CI, 1.0 to 5.4]; P = 0.005), but not in 24 h
SBP (3.1 mm Hg [95% CI, 0.6 to 6.7]; P = 0.10), compared with the control group (Figure 2). Moreover,
the percentage of patients with nocturnal BP dipper pattern after the 12 week follow-up was greater
in the CPAP group (35.9% vs. 21.6%; adjusted odds ratio [OR], 2.4 [95% CI, 1.2 to 5.1]; P = 0.02). Finally,
as seen in previous studies, there was a significant positive correlation between hours of CPAP use and
the decrease in 24 h mean BP (r = 0.29, P = 0.006), SBP (r = 0.25; P = 0.02) and DBP (r = 0.30, P = 0.005.
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Table 2. Characteristics of randomised clinical trials on the effect of continuous positive airway pressure on blood pressure levels in patients with sleep apnoea and
resistant/refractory hypertension.
Studies Randomisation(Complete Follow-Up) Age BMI ESS Anti-HT Drugs
SBP/DBP (mmHg)
at Entry BP Measure AHI, Sleep Study CPAP Use Follow-Up
Lozano et al.,
2010 [77]
29 to CPAP
35 to control 59.2 (9.9) 30.8 (5) 6.14 (3.3) 3.48 (0.57) 129.9 (13.7)/76 (10) ABPM
52.3 (21.5)
Full PSG 5.6 (1.52) 3 months
Pedrosa et al.,
2013 [83]
19 to CPAP
16 to control 56 (1) 32 (28–39) 10 (1) 4 (4–5) 162 (4)/97 (2) ABPM
29 (24–48)
PSG 6.01 (0.2) 6 months
Martinez-Garcia
et al., 2013 [17]
98 to CPAP
96 to control 56 (9.5) 34.1 (5.4) 9.1 (3.7) 3.8 (0.9) 144.2 (12.5)/83 (10.5) ABPM
40.4 (18.9)
RP 5 (1.9) 3 months
De Oliveira et
al., 2014 [78]
24 to CPAP
23 to sham 59.4 (7.7) 29.8 (4.4) 10 (6–15) 4 (1) 148 (17)/88 (13) ABPM
20 (18–1)
RP
5.3 (4.1–7.1)
Median (IQR) 8 weeks
Muxfeldt et al.,
2015 [71]
57 to CPAP
60 to control 60.5 (8.2) 33.4 (5.3) 11 (6) 5 (3–8) 129 (16)/75 812) ABPM
41 (21)
PSG 4.8 (median) 6 months
Navarro et al.,
2019 * [80]
23 to CPAP
19 to control
61.1 (8.3)
vs. 56.7 (9)
34.9 (5.4) vs.
34.1 (6.8)
9 (4) vs.
8.9 (3.8)
5 (5–6) vs. 5 (5–6)
(median, IQR)
154.1 (12.2)/82.9 (14.2)
149(11.5)/84.1 (10.8) ABPM
42.7 (17.2) vs.
40.4 (20.3)
RP
5.2 (1.5) 3 months
* This study investigate the effect of CPAP on refractory hypertension. Data expressed by mean (standard deviation), unless indicated otherwise. BMI: Body Mass Index; ESS: Epworth
Sleepiness Scale; anti-HT: antihypertensive; SBP: Systolic Blood Pressure; DBP: Diastolic Blood Pressure; AHI: Apnoea Hypopnoea Index; CPAP: Continuous Positive Airway Pressure;
ABPM: 24h-Ambulatory Blood Pressure Monitoring; RP: Respiratory Polygraphy; PSG: Polysomnography; IQR: Interquartile range).
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The last published meta-analysis was performed by Lei et al. [88] and included six RCTs.
The pooled estimates of the changes in SBP and DBP (as assessed by 24h-ABPM) were 5.40 mmHg
(95% CI: 9.17 to 1.64; p = 0.001; and 3.86 mmHg (95% CI: 6.41 to 1.30; p = 0.00001), respectively.
After this meta-analysis, an additional RCT was published by a French group (RHOOSAS study) [81]
in 2018. Sixty-two patients with RH who were taking a mean of 3.7 antihypertensive drugs were
included. Sixty percent of the patients presented OSA. Three months of effective CPAP significantly
decreased night-time SBP by 6.4 mmHg and heart rate by 6.0 bpm, compared to sham CPAP. Moreover,
their leptin concentrations were significantly lower those of non-OSA patients (9 (6; 15) vs. 17 (6; 29)
ng/mL) but these increased after six months of CPAP.
Some interesting additional data on the effect of CPAP in patients with RH or RfH hypertension
can be found in some other studies: Campos-Rodríguez et al. [93] reported that patients with RH had
good adherence to CPAP after one year of follow-up (74.5%), demonstrating that a long-term RCT on
these patients is feasible. Furthermore, a post hoc analysis of the HIPARCO study concluded that the
effect of CPAP on RfH is even greater than that seen in patients with RH (without RfH). In this study,
a total of 98 patients were randomised to CPAP (19 with RfH and 79 with RH) and 96 were randomised
to usual care (21 with RfH and 75 with RH). BP readings dropped more markedly in those patients
with RfH than in those with RH, in both 24 h SBP (9 vs. 1.6 mmHg, p = 0.021) and 24 h DBP (7.3 vs.
2.3 mmHg, p = 0.074), especially at night (11.3 vs. 3.8, p = 0.121 and 8.8 vs. 2.2, p = 0.054). The adjusted
difference between groups was statistically significant in 24 h SBP levels (7.4 mm Hg, p = 0.021) [80].
Moreover, one of the factors associated with the progression over time from an RH to an RfH phenotype
in those patients with OSA was non-adherence to CPAP treatment [94]. Recently, Sapiña et al. [92]
published the methodology for SARAH (NCT03002558). This will be a multi-centre, prospective,
observational cohort study in which a total of 1371 patients with RH have been enrolled, and they will
be followed up once a year for five years. At their inclusion, all the subjects will undertake an ABPM
and a sleep study. Socio-demographic, clinical and cardiovascular variables will be collected at baseline
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and follow-up, and OSA patients will be managed according to local standard practice. Based on the
OSA diagnosis and its treatment, three cohorts of RH patients will be defined: non-OSA, treated OSA
and non-treated OSA. This study will help elucidate the long-term impact of OSA treatments on blood
pressure control and cardiovascular outcomes in patients with RH. Along the same lines, the final
results of the long-term follow-up of the patients from the HIPARCO study (HIPARCO-2 study) will be
published soon, throwing light on the effect of CPAP on cardiovascular events and BP after five years
of follow-up.
Beyond the known effect on the reduction in the sympathetic activity of CPAP, this treatment
has also been shown to affect aldosterone concentration. De Souza et al. [82] demonstrated that only
optimal CPAP treatment reduced aldosterone excretion in patients with uncontrolled RH, while the
effect was borderline in an intention-to-treat analysis. Although these results are not definitive, they do
suggest that CPAP treatment might improve cardiovascular outcomes by reducing aldosterone excess
in RH patients with OSA. Furthermore, a previous study by Lloberes et al. [79] on the same topic
observed that CPAP achieved a significant decrease in aldosterone concentration (26.1 ± 11.2 vs.
18.9 ± 10.1 ng/dL; p < 0.041) in patients with white-coat RH. After adjustment, a weak but significant
association was found between cumulative time spent with SaO2 below 90% and baseline aldosterone
concentration (p < 0.047), and between changes in aldosterone concentration and changes in office DBP
(p < 0.020).
Moreover, Sanchez de la Torre et al. [75] observed three miRNAs obtained from responders and
non-responders to CPAP treatment from the HIPARCO study, which provided a discriminatory predictive
model for a favourable BP response to CPAP (area under the curve: 0.92; p = 0.01). CPAP treatment
also significantly altered a total of 47 plasma miRNAs and decreased aldosterone-to-renin ratios in the
responder group (p = 0.016) but not in the non-responder group.
Finally, another study analysed the additional effect of CPAP on renal denervation. Linz et al. [63]
published data taken from 1868 patients on the SYMPLICITY registry (NCT01534299): 205 had self-reported
OSA, and the authors concluded that renal denervation resulted in significant BP reductions after 6 months
in hypertensive patients with and without OSA, regardless of CPAP usage in the case of the OSA patients.
In conclusion, and taking into account all these published findings on the effect of CPAP on BP
levels and other characteristics in patients with RH or RfH, it seems that:
1. The reduction in BP levels is greater in RH patients (especially in those with a lack of BP control)
than in normotensive or well-controlled hypertensive patients (approximately 2 mmHg)
2. The degree of reduction in BP levels is similar to those achieved by some antihypertensive drugs,
especially in patients with RfH.
3. There is a positive and linear correlation between the hours of use of CPAP and the reduction
in BP levels.
4. CPAP treatment produces an increase in the percentage of the normal nocturnal BP dipper pattern.
5. CPAP decreases both the sympathetic activity and the level of aldosterone concentration in both
RfH and RH patients, and these could constitute some of the pathophysiological action mechanisms
involved in this treatment.
6. The effect on RH of CPAP treatment combined with other pharmacological or non-pharmacological
interventions such as renal denervation and antihypertensive drugs is still not known.
6. Future Challenges
The relationship between RH (especially RfH) and OSA has been detected recently and so many
future challenges still await us, and they need to be tackled urgently for several reasons. On the one
hand, there are few therapeutic options available for patients with RH/RfH, despite their ominous
prognosis, while on the other hand, the prevalence of OSA among these patients is significantly high,
and the treatment with CPAP has proved effective in reducing BP levels, being established as a new
therapeutic way. To the date, beyond the magnitude of the effect of CPAP on BP in RH patients that
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might be even more important in RfH subjects, there is the need to set agreed criteria regarding how
to fit in the multidimensional management of RH/RfH (Table 3) the potential role of the beneficial
hemodynamic effects of this OSA treatment. Table 4 details some of the most important challenges
associated with this relationship.
Table 3. The effect on BP and on OSA severity of different treatment strategies in subjects with
resistant/refractory hypertension.
Treatment Strategy Effect on BP Effect on OSA
Lifestyle and diet measures
Sodium restriction Decrease of BP(*) Improvement of OSA severity
Weight reduction Decrease of BP(*) Improvement of OSA severity
Regular physical exercise Decrease of BP (*)
Specific diet (Mediterranean, DASH) Decrease of BP(*) (*)
Antihypertensive drugs
Diuretics Decrease of BP Improvement of OSA severity
Spironolactone Decrease of BP(Fourth drug of choice) Improvement of OSA severity
Other antihypertensive drugs Decrease of BP (*)
Invasive procedures
Renal ablation Probable decrease of BP(*) Improvement of OSA severity
OSA treatment (devices)
CPAP treatment Decrease of BPespecially in RfH Control of the disease.
Other OSA treatments Decrease of BP(*) Control of the disease.
(*) Further research is needed.
Table 4. Future challenges in the relationship between RH/RfH and OSA.
To understand the pathophysiological mechanisms that distinguish RH and RfH, and how OSA and CPAP
treatment can influence them.
To assess the best combined therapeutic strategy in patients with RH/RfH and OSA.
To determine the added value of CPAP to the different antihypertensive treatments,
including renal denervation.
To analyse the effect of long-term CPAP on blood pressure and cardiovascular events in patients with RH/RfH.
To determine the various biomarker predictors of a good BP response to CPAP.
To group homogeneous clinical phenotypes in terms of clinical presentation,
prognosis and response to treatment.
To determine the role of confounders in the relationship between RH/RfH and OSA, particularly obesity.
The contrast in office BP measures and 24 h ABPM results makes it possible to define different phenotypes
of RH, according to whether the monitoring results are congruent (controlled or sustained) or not (white coat or
masked). At present, the predictive value of each phenotype with respect to the effect of CPAP is still unknown.
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7. Conclusions
Patients with RH/RfH have a high cardiovascular risk and few therapeutic options. Recently,
a close relationship between these phenotypes of hypertensive patients and OSA has been discovered.
Both diseases seem to alter similar pathophysiological mechanisms. This has meant that in clinical
studies, the prevalence of OSA in patients with RH/RfH is very high and that treatment with CPAP,
which eliminates nocturnal respiratory events, is able to decrease BP levels in a clinically significant
way. There are still many unanswered questions that pose future challenges such as the ideal combined
treatment in these patients, or the role that long-term CPAP can play in the incidence of cardiovascular
events. However, given the great cardiovascular risk of these patients and their scarce therapeutic
options, ruling out the presence of an OSA is important since this is a potentially treatable disorder.
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